Hormonal
GLP-1 receptor agonists (e.g., semaglutide, liraglutide) significantly reduce major adverse cardiovascular events (MACE) and promote substantial weight loss in patients with or without diabetes, addressing core CMS components.
If you have obesity and cardiovascular risk factors, GLP-1 agonists like semaglutide or liraglutide are highly effective. They help you lose significant weight and reduce your risk of heart attacks and strokes. These are typically injected weekly or daily. Discuss with your doctor if you are a candidate, especially if you have obesity-related complications.
The SELECT trial provided compelling evidence that semaglutide reduced MACE by 20% in individuals without diabetes who are overweight or obese... The STEP trials demonstrated that semaglutide induces substantial and sustained weight loss.
Why this rating
Supported by large, landmark RCTs (LEADER, SUSTAIN-6, SELECT, STEP).
Source
Expanding the Role of Novel Therapeutics in Cardiometabolic Syndrome: Beyond Heart Failure and Diabetes
Hyun‐Jin Kim · CardioMetabolic Syndrome Journal · 2025
DOI 10.51789/cmsj.2025.5.e4
More from this paper
- Combination therapy with ARNIs and SGLT2 inhibitors produces synergistic cardiovascular, metabolic, and renal benefits in cardiometabolic syndrome (CMS) patients, though implementation is hindered by hypotension risks and cost.Good
- Novel mineralocorticoid receptor antagonists (MRAs) like finerenone reduce cardiovascular events and slow CKD progression in CMS patients with lower hyperkalemia risk compared to traditional MRAs.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →